Clinical Trial Results:
HZC112352:Estudio de 12 semanas de duración para evaluar la función pulmonar durante 24 horas de Furoato de Fluticasona /Vilanterol (FF/VI) 100/25 µg en polvo para inhalación, una vez al día, en comparación con Propionato de Fluticasona/ Salmeterol 250/50 µg en polvo para inhalación, dos veces al día, en sujetos con enfermedad pulmonar obstructiva crónica (EPOC).
HZC112352: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD).
Summary
|
|
EudraCT number |
2010-023419-33 |
Trial protocol |
ES DE IT |
Global completion date |
24 Jan 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Feb 2016
|
First version publication date |
06 Nov 2014
|
Other versions |
|
Summary report(s) |
112352-FDAAA-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.